Atrium Therapeutics RNA 深 滬
等待開盤 08-22 09:30:00 美东时间
13.24
-0.240
-1.78%
華盛通- 最 高13.53
- 今 開13.53
- 成交量 11.95万股
- 最 低 12.96
- 昨 收 13.48
- 總市值 2.26亿
- 52周最高 73.06
- 市盈率 靜 --
- 換手率 0.70%
- 52周最低 11.13
- 委 比 89.54%
- 總股本 1710.56万
- 歷史最高 73.06
- 量 比 1.28
- 振 幅 4.23%
- 歷史最低 4.825
- 每 手 1
- 風險率 26.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on August 20, 2026 under the Company's 2026 Empl...
08-21 06:23
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Atrium Therapeutics (NASDAQ:RNA) with a Buy and maintains $25 price target.
08-15 01:27
财报速睇 | Atrium Therapeutics 2026财年Q2营收0.03亿美元，同比下降21.9%；归母净利润亏损0.20亿美元，同比亏损扩大56.7%
华盛资讯8月14日讯，Atrium Therapeutics公布2026财年Q2业绩，公司Q2营收0.03亿美元，同比下降21.9%，归母净利润亏损0.20亿美元，同比亏损扩大56.7%。
08-14 05:32
财报速睇 | Atrium Therapeutics 2026财年Q2营收0.03亿美元，同比下降21.9%；归母净利润亏损0.20亿美元，同比亏损扩大56.7%
华盛资讯8月14日讯，Atrium Therapeutics公布2026财年Q2业绩，公司Q2营收0.03亿美元，同比下降21.9%，归母净利润亏损0.20亿美元，同比亏损扩大56.7%。
08-14 05:22
Atrium Therapeutics Q2 EPS $(1.18) Misses $(1.01) Estimate, Sales $3.004M Beat $2.000M Estimate
Atrium Therapeutics (NASDAQ:RNA) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.01) by 16.83 percent. This is a 2.48 percent increase over losses of $(1.21) per share from the same period last year. The company reported quarterly sales of $3.004 mil...
08-14 04:49
Atrium Therapeutics, Inc. (RNA) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Atrium Thera...
08-14 01:15
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Buy rating and announces Price Target of $25.
08-06 19:12
Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA)
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rat...
07-16 17:45
